Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 81 | 2 | 73 | −6 |
| Shares | 43.6M | 2.22M | 43.6M | +2.25M (+5.4%) |
| Value | $105.5M | $5.38M | $107.7M | +$7.57M (+7.6%) |
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (11)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 2,331,530 | $5.78M | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 23,015 | $57.1K | 0.00% |
| SEI Investments Co | 21,782 | $54.0K | 0.00% |
| Acadian Asset Management LLC | 18,643 | $46.0K | 0.00% |
| SG Americas Securities, LLC | 17,772 | $44.0K | 0.00% |
| Fortitude Advisory Group L.L.C. | 13,300 | $33.0K | 0.02% |
| Federation des caisses Desjardins du Quebec | 1,500 | $3.72K | 0.00% |
| Sterling Capital Management LLC | 133 | $330 | 0.00% |
| Nisa Investment Advisors, LLC | 100 | $248 | 0.00% |
| Capital Performance Advisors LLP | 52 | $129 | 0.00% |
| CWM, LLC | 168 | $0 | 0.00% |
Sold out (17)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Man Group plc | 105,777 | $256.0K |
| Schonfeld Strategic Advisors LLC | 73,619 | $178.2K |
| Murchinson Ltd. | 56,250 | $136.1K |
| D. E. Shaw & Co., Inc. | 55,007 | $133.1K |
| Bank of Montreal | 30,885 | $76.6K |
| Marathon Trading Investment Management LLC | 26,298 | $63.6K |
| Walleye Capital LLC | 18,801 | $45.5K |
| Pinnacle Associates Ltd | 18,020 | $43.6K |
| Oxford Asset Management LLP | 15,304 | $37.0K |
| Stifel Financial Corp | 13,650 | $33.0K |
| Engineers Gate Manager LP | 11,479 | $27.8K |
| Gladius Capital Management LP | 10,939 | $26.5K |
| Cubist Systematic Strategies, LLC | 8,880 | $21.5K |
| Point72 (DIFC) Ltd | 4,018 | $9.72K |
| Sandy Spring Bank | 1,500 | $3.63K |
| Kelly Financial Services LLC | 944 | $2.29K |
| Redwood Wealth Management Group, LLC | 800 | $1.94K |
Not filed for Q3 2024 yet (2)
Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,158,661 | $5.22M |
| Susquehanna Fundamental Investments, LLC | 62,518 | $151.3K |